Primary_lymphoid and hematopoietic malignant neoplasms

DOID EFO MESH SNOMED PheWeb

lymphoma: A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.

Endpoint definition

↥

Name	CD2_PRIMARY_LYMPHOID_HEMATOPOIETIC
Long name	Primary_lymphoid and hematopoietic malignant neoplasms
Include	CD2_HODGKIN_LYMPHOMA, CD2_FOLLICULAR_LYMPHOMA, CD2_NONFOLLICULAR_LYMPHOMA, CD2_TNK_LYMPHOMA, CD2_NONHODGKIN_NAS, CD2_OTHER_SPECIAL_TNK_LYMPHOMA, CD2_IMMUNOPROLIFERATIVE, CD2_MULTIPLE_MYELOMA_PLASMA_CELL, CD2_LYMPHOID_LEUKAEMIA, CD2_MYELOID_LEUKAEMIA, CD2_MONOCYTIC_LEUKAEMIA, CD2_OTHER_LEUKAEMIA_SPECIFIED, CD2_LEUKAEMIA_NAS, CD2_PRIMARY_LYMPHOID_HEMATOPOIETIC_NAS
Level in the ICD-hierarchy	2
First defined in version	DF2

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	3537	1599	1938
Unadjusted prevalence (%)	1.63	1.30	2.06
Mean age at first event (years)	60.10	57.95	61.88
Case fatality at 5-years (%)	13.40	11.01	15.38

Longitudinal metrics

	All	Female	Male
Median nb. of events per indiv.	6.0	6.0	6.0
Recurrence at 6 months (%)	73.08	71.67	74.25

Survival analyses between endpoints

↥

Plot

before Primary_lymphoid and hematopoietic malignant neoplasms
after Primary_lymphoid and hematopoietic malignant neoplasms

Loading survival analyses plot…

Table

Loading survival analyses table…

Drugs most likely to be purchased after Primary_lymphoid and hematopoietic malignant neoplasms

↥